
KIDS
OrthoPediatrics Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.780
Open
22.580
VWAP
--
Vol
175.51K
Mkt Cap
551.61M
Low
22.045
Amount
--
EV/EBITDA(TTM)
--
Total Shares
23.83M
EV
566.02M
EV/OCF(TTM)
--
P/S(TTM)
2.43
OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
61.40M
+16.28%
--
--
63.92M
+17.13%
--
--
61.64M
+17.04%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for OrthoPediatrics Corp. (KIDS) for FY2025, with the revenue forecasts being adjusted by 0.58% over the past three months. During the same period, the stock price has changed by 6.96%.
Revenue Estimates for FY2025
Revise Upward

+0.58%
In Past 3 Month
Stock Price
Go Up

+6.96%
In Past 3 Month
6 Analyst Rating

54.92% Upside
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 34.50 USD with a low forecast of 26.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy

54.92% Upside
Current: 22.270

Low
26.00
Averages
34.50
High
42.00

54.92% Upside
Current: 22.270

Low
26.00
Averages
34.50
High
42.00
BTIG
Buy
maintain
$38 -> $40
2025-07-14
Reason
BTIG
Price Target
$38 -> $40
2025-07-14
maintain
Buy
Reason
BTIG raised the firm's price target on OrthoPediatrics to $40 from $38 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Piper Sandler
Matt O'Brien
Overweight
downgrade
$40 -> $30
2025-05-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$40 -> $30
2025-05-08
downgrade
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on OrthoPediatrics to $30 from $40 and keeps an Overweight rating on the shares. The firm notes OrthoPediatrics reported Q1 results which beat soundly on the top-line and gross margins too. Adjusted EBITDA was a little light, but Piper just did not model this metric appropriately and the progress here is completely intact. The firm believes investors need to buy the stock at these levels as management is building a valuable pediatric technology provider that is underappreciated by the market.
Truist Securities
Richard Newitter
Hold
Maintains
$26 → $24
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$26 → $24
2025-04-11
Maintains
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on OrthoPediatrics to $24 from $26 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
Needham
Mike Matson
Strong Buy
Reiterates
$42
2025-04-09
Reason
Needham
Mike Matson
Price Target
$42
2025-04-09
Reiterates
Strong Buy
Reason
Lake Street
Ben Haynor
Strong Buy
Initiates
$37
2025-04-07
Reason
Lake Street
Ben Haynor
Price Target
$37
2025-04-07
Initiates
Strong Buy
Reason
Lake Street initiated coverage of OrthoPediatrics with a Buy rating and $37 price target. OrthoPediatrics has proven out its founding thesis that a focused pediatric orthopedics firm is needed and can generate strong economic returns, says the analyst, who argues that the company "occupies a Goldilocks position in an overlooked market."
Citizens Capital Markets
David Turkaly
Buy
Reiterates
$50
2025-03-21
Reason
Citizens Capital Markets
David Turkaly
Price Target
$50
2025-03-21
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for OrthoPediatrics Corp (KIDS.O) is -18.28, compared to its 5-year average forward P/E of -46.73. For a more detailed relative valuation and DCF analysis to assess OrthoPediatrics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-46.73
Current PE
-18.28
Overvalued PE
-28.18
Undervalued PE
-65.27
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
341.82
Current EV/EBITDA
31.24
Overvalued EV/EBITDA
855.42
Undervalued EV/EBITDA
-171.78
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
6.58
Current PS
2.26
Overvalued PS
9.79
Undervalued PS
3.38
Financials
Annual
Quarterly
FY2025Q1
YoY :
+17.29%
52.41M
Total Revenue
FY2025Q1
YoY :
+12.53%
-10.94M
Operating Profit
FY2025Q1
YoY :
+36.57%
-10.66M
Net Income after Tax
FY2025Q1
YoY :
+35.29%
-0.46
EPS - Diluted
FY2025Q1
YoY :
-36.25%
-8.38M
Free Cash Flow
FY2025Q1
YoY :
+1.39%
73.00
Gross Profit Margin - %
FY2025Q1
YoY :
-40.68%
-17.51
FCF Margin - %
FY2025Q1
YoY :
+16.43%
-20.34
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 146.33% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
721.7K
USD
5
6-9
Months
0.0
USD
0
0-12
Months
293.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 114.29% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
3.0K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
45.0K
Volume
Months
6-9
1
21.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 146.33% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
721.7K
USD
5
6-9
Months
0.0
USD
0
0-12
Months
293.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KIDS News & Events
Events Timeline
2025-07-16 (ET)
2025-07-16
07:04:11
OrthoPediatrics announces Global POISE Study reaches milestone of 600 implants

2025-05-07 (ET)
2025-05-07
17:00:02
OrthoPediatrics narrows FY25 revenue view to $236M-$242M from $235M-$242M

2025-05-07
16:58:16
OrthoPediatrics reports Q1 EPS (39c), consensus (44c)

Sign Up For More Events
Sign Up For More Events
News
9.5
07-28Yahoo FinancePinnedHere’s Why OrthoPediatrics Corp. (KIDS) Drifted Lower in Q2
8.0
07-19NASDAQ.COMNotable Friday Option Activity: LQDA, ABNB, KIDS
5.0
04-08NewsfilterOrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
Sign Up For More News
People Also Watch

IMXI
International Money Express Inc
9.480
USD
-0.42%

LXU
LSB Industries Inc
8.710
USD
+0.81%

GES
Guess? Inc
13.250
USD
-3.28%

PGY
Pagaya Technologies Ltd
29.080
USD
-6.47%

TTI
Tetra Technologies Inc
3.820
USD
+1.60%

TK
Teekay Corp Ltd
7.760
USD
+1.04%

CURV
Torrid Holdings Inc
2.620
USD
-0.76%

EVER
EverQuote Inc
24.270
USD
-3.69%

USNA
USANA Health Sciences Inc
30.260
USD
-3.75%

MNRO
Monro Inc
16.320
USD
+0.12%
FAQ

What is OrthoPediatrics Corp (KIDS) stock price today?
The current price of KIDS is 22.27 USD — it has decreased -0.54 % in the last trading day.

What is OrthoPediatrics Corp (KIDS)'s business?

What is the price predicton of KIDS Stock?

What is OrthoPediatrics Corp (KIDS)'s revenue for the last quarter?

What is OrthoPediatrics Corp (KIDS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for OrthoPediatrics Corp (KIDS)'s fundamentals?

How many employees does OrthoPediatrics Corp (KIDS). have?
